Algocare Ltd.
Immersive ContentOther
- Website : https://algocare.ai
- Location : 6 47 Mareunnae-ro, Jung-gu, Seoul, Republic of Korea
Algocare Inc. is a healthcare startup founded in November 2019. Under the leadership of CEO Jiwon Jeon—a graduate of Seoul University’s College of Law and its Graduate School (Master's degree) who previously worked as a regulatory compliance expert at Kim & Chang—a team of experts in medicine, pharmacy, artificial intelligence, hardware, and software has come together to conduct advanced technological research.
The company developed NaaS (Nutrition as a Service), a personalized nutrition management solution that integrates AI, IoT dispensers, and micro-formulation nutrients. With this innovation, Algocare won the CES Innovation Awards six times (from 2021 to 2024, and in 2026), gaining international recognition for its originality and innovation. The company's commercial viability has also been well-proven through securing 15.4 billion KRW in investment.
Algocare’s proprietary high-performance AI algorithm precisely analyzes users' medical data (health screenings and prescription histories), survey data, and real-time physical conditions to automatically calculate the types and amounts of nutritional ingredients required for an individual down to the milligram ($mg$) level.Based on this encrypted health data, the compact home and corporate appliance automatically blends and dispenses ultra-small, micro-formulated nutrients within 5 to 10 seconds. It boasts exceptional precision, featuring a low error rate of less than 0.05% and a dispensing accuracy of over 99.3%.
The company developed NaaS (Nutrition as a Service), a personalized nutrition management solution that integrates AI, IoT dispensers, and micro-formulation nutrients. With this innovation, Algocare won the CES Innovation Awards six times (from 2021 to 2024, and in 2026), gaining international recognition for its originality and innovation. The company's commercial viability has also been well-proven through securing 15.4 billion KRW in investment.
Algocare’s proprietary high-performance AI algorithm precisely analyzes users' medical data (health screenings and prescription histories), survey data, and real-time physical conditions to automatically calculate the types and amounts of nutritional ingredients required for an individual down to the milligram ($mg$) level.Based on this encrypted health data, the compact home and corporate appliance automatically blends and dispenses ultra-small, micro-formulated nutrients within 5 to 10 seconds. It boasts exceptional precision, featuring a low error rate of less than 0.05% and a dispensing accuracy of over 99.3%.
Video
Business Description
B2B Market: In the first half of 2023, Algocare officially launched "Algocare at Work," a corporate welfare product. It has been successfully supplied to over 90 major conglomerates and leading enterprises, including Hyundai Motor Company, Kia, LG Energy Solution, SK Square, and POSCO E&C.
B2C & Global Expansion: Leveraging this success, following the domestic launch of the home-use (B2C) lineup product, Algocare E1, the company is currently pushing forward with its entry into U.S. e-commerce and offline retail channels.
Intellectual Property (IP): Algocare has successfully registered a total of 27 patents, including domestic and international applications, with one patent registered each in the United States and Japan. Holding a robust portfolio of over 50 intellectual property rights, the company has secured exclusive rights to its personalized dosage calculation and tracking technologies.
B2C & Global Expansion: Leveraging this success, following the domestic launch of the home-use (B2C) lineup product, Algocare E1, the company is currently pushing forward with its entry into U.S. e-commerce and offline retail channels.
Intellectual Property (IP): Algocare has successfully registered a total of 27 patents, including domestic and international applications, with one patent registered each in the United States and Japan. Holding a robust portfolio of over 50 intellectual property rights, the company has secured exclusive rights to its personalized dosage calculation and tracking technologies.
